1-2 of 2
Jim Atkins
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, PhD, Nyla A. Heerema, PhD, Weiqiang Zhao, MD PhD, Allison M Booth, Wei Ding, MD PhD, Nancy L. Bartlett, MD, Danielle M. Brander, MD, Paul Barr, MD, Kerry A. Rogers, MD, Sameer A. Parikh, MD, Steven Coutre, MD, Arti Hurria, MD, Gerard Lozanski, MD, Sreenivasa Nattam, MD, Richard A. Larson, MD, Harry P. Erba, MDPhD, Mark R. Litzow, MD, Carolyn Owen, Jim Atkins, Jeremy S. Abramson, MD MMSc, Richard F. Little, MD MPH, Scott E. Smith, MD PhD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD, John C. Byrd, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 6.
https://doi.org/10.1182/blood-2018-99-116653
Published: 2018
Journal Articles

Randomized Phase 2 Trial of Ofatumumab and Bendamustine Versus Ofatumumab, Bendamustine, and Bortezomib Induction and Maintenance Therapy in Patients (pts) with Previously Untreated High Risk Follicular Lymphoma (FL): Results from CALGB 50904 (Alliance)

Kristie A. Blum, MD, Sin-Ho Jung, PhD, Ian Barak, MS, Eric D. Hsi, MD, Nina D. Wagner-Johnston, MD, Beth Christian, MD, Jim Atkins, Bruce D. Cheson, MD, John P. Leonard, MD, Nancy L. Bartlett, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 485.
https://doi.org/10.1182/blood.V130.Suppl_1.485.485
Published: 2017